Welcome to our dedicated page for Cyclacel Pharma news (Ticker: CYCC), a resource for investors and traders seeking the latest updates and insights on Cyclacel Pharma stock.
Cyclacel Pharmaceuticals (CYCC) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through cell cycle regulation. This resource provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of CYCC's progress with its CDK and PLK inhibitor pipeline, including fadraciclib and plogosertib development. Stay informed about critical updates across multiple news categories: clinical trial results, regulatory filings, research collaborations, and intellectual property developments.
Our curated news collection enables efficient tracking of the company's precision medicine approach and therapeutic innovations in oncology. Regular updates ensure you never miss pivotal announcements about trial phases, partnership agreements, or scientific presentations.
Bookmark this page for streamlined access to verified CYCC developments. Check back frequently for objective reporting on advancements in targeted cancer treatment research and their implications for hematology/oncology care.
Cyclacel Pharmaceuticals has initiated dosing for the first patient in a multi-cohort Phase 1/2 trial of fadraciclib, a next-generation CDK2/9 inhibitor, targeting patients with leukemias and myelodysplastic syndromes (MDS). This follows the company's recent progress in a solid tumor and lymphoma study. The trial aims to define the recommended Phase 2 dose and will explore fadraciclib both as a single agent and in combination therapies, potentially establishing new treatment options for these patients.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) will announce its third quarter financial results and provide a business update on November 10, 2021, at 4:30 p.m. Eastern Time. The company specializes in developing innovative cancer medicines targeting cell cycle and transcriptional regulation. Key programs include fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor. A conference call will be hosted where stakeholders can participate and access details through the company's website.
Cyclacel Pharmaceuticals will participate in three investor conferences in September 2021, highlighting its commitment to engaging with the investment community. The conferences include the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 20-22, and the Cantor Fitzgerald Global Healthcare Conference from September 27-30. Cyclacel is focused on developing innovative cancer medicines and will showcase its pipeline during these events.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced the dosing of its first three patients with advanced solid tumors in the Phase 1/2 trial of oral fadraciclib. This trial will assess the drug's efficacy across various cancer types, building on previous positive data. The company is also preparing to initiate the CYC140 study targeting KRAS mutant cancers. As of June 30, 2021, Cyclacel reported $43.6 million in cash, sufficient to fund operations into early 2023. However, the net loss increased to $5.1 million for Q2 2021 from $2.2 million in Q2 2020.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) plans to announce its second quarter financial results and provide a business update on August 11, 2021. A conference call will occur at 4:30 p.m. EDT. The company is also participating in the BTIG Virtual Biotechnology Conference on August 9, 2021, featuring a fireside chat at 9:00 a.m. EDT. Cyclacel focuses on developing cancer treatments, with a pipeline that includes fadraciclib and CYC140. Investors are advised to consider forward-looking statements that involve risks and uncertainties.
Cyclacel Pharmaceuticals announced the dosing of the first patient in a Phase 1/2 trial for fadraciclib, a next-generation CDK2/9 inhibitor, targeting advanced solid tumors and lymphomas. This study marks a significant milestone in their clinical development program, which aims to establish fadraciclib's safety and efficacy across various cancer types, including breast and endometrial cancers. With promising preclinical data indicating substantial tumor reduction in some patients, Cyclacel anticipates further trials and potential regulatory submissions in the near future.
Cyclacel Pharmaceuticals announced its participation in the Ladenburg Thalmann’s Virtual 2021 Healthcare Conference set for July 13-14, 2021. Spiro Rombotis, President & CEO, will present Cyclacel’s business overview and engage in an analyst-led fireside chat.
Presentation details:
- Date: July 14, 2021
- Time: 10:30-10:55 am EDT
- Location: Virtual; Track 1
The archived webcast will be available on Cyclacel's website for 90 days following the event.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced FDA authorization for its IND application of oral fadraciclib, a CDK2/9 inhibitor targeting solid tumors. The Phase 1b/2 trial will focus on various cancers, including KRAS mutant types. The company reported $47.8 million in cash as of March 31, 2021, an increase from $33.4 million at year-end 2020, thanks to a recent equity financing of $13.5 million. Cyclacel aims to initiate multiple clinical studies in 2021, leveraging recent research supporting fadraciclib's efficacy against KRAS-mutated cancers.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) will release its first quarter financial results on May 12, 2021, followed by a conference call at 4:30 p.m. EDT. The company focuses on developing innovative cancer medicines, including fadraciclib and CYC140. These therapies target cancer biology through cell cycle and transcriptional regulation. Cyclacel's ongoing strategy aims to establish a diverse biopharmaceutical business centered on oncology and hematology.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) has successfully closed its underwritten public offering of 2,078,214 shares at $7.00 per share, raising approximately $14.5 million in gross proceeds. The offering included the full exercise of the underwriter's over-allotment option. Funds will be utilized for growth strategies, working capital, and R&D expenses. The offering was conducted under an effective shelf registration statement by the SEC. Oppenheimer & Co. Inc. served as the sole book-running manager for this public offering.
